Effect of iGlarLixi on continuous glucose monitoring—measured time in range in insulin‐naive adults with suboptimally controlled type 2 diabetes

Documenti analoghi

• Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli‐ SWITCH study
  di: Martin Haluzík, et al.
  Pubblicazione: (2025)
• Safety and clinical effectiveness of iGlarLixi in people with type 2 diabetes mellitus in Mexico
  di: Juan Rosas‐Guzman, et al.
  Pubblicazione: (2025)
• Real‐life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use
  di: Jochen Seufert, et al.
  Pubblicazione: (2024)
• The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
  di: Ming Liu, et al.
  Pubblicazione: (2024)
• iGlarLixi : A titrateable fixed‐ratio combination of basal insulin + GLP‐1 receptor agonist—An effective type 2 diabetes treatment option in China
  di: Miao Yu
  Pubblicazione: (2025)